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Abstract 
Little is known about the needs or characteristics of transgender individuals in substance abuse treatment 
settings. Transgender (n = 199) and non-transgender (cisgender, n = 13,440) individuals were compared on 
psychosocial factors related to treatment, health risk behaviors, medical and mental health status and 
utilization, and substance use behaviors within a database that documented individuals entering substance 
abuse treatment in San Francisco, CA from 2007 to 2009 using logistic and linear regression analyses (run 
separately by identified gender). Transgender men (assigned birth sex of female) differed from cisgender men 
across many psychosocial factors, including having more recent employment, less legal system involvement, 
greater incidence of living with a substance abuser, and greater family conflict, while transgender women 
(assigned birth sex of male) were less likely to have minor children than cisgender women. Transgender women 
reported greater needle use, and HIV testing rates were greater among transgender women. Transgender men 
and women reported higher rates of physical health problems, mental health diagnoses, and psychiatric 
medications, but there were no differences in service utilization. There were no differences in substance use 
behaviors except that transgender women were more likely to endorse primary methamphetamine use. 
Transgender individuals evidence unique strengths and challenges that could inform targeted services in 
substance abuse treatment. 
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1. Introduction 
Little is known about the substance use behaviors of transgender1 persons as national substance use 
surveillance systems and epidemiological surveys predominantly assume that all participants are “cisgender,” 
meaning that a participant's gender is congruent with the sex assigned at birth, even though transgender 
individuals are estimated to comprise between 0.3 and 0.6% of the population (Conron, Scott, Stowell, & 
Landers, 2012). Recent evidence from state-level health surveillance systems indicates that transgender persons, 
relative to their cisgender counterparts, are at elevated risk for smoking cigarettes, although not at elevated risk 
for binge drinking (Conron et al., 2012). A meta-analysis of available research indicates high rates of substance 
use among transgender individuals (Herbst et al., 2008), while local needs assessment research of transgender 
individuals in Washington, DC identified high rates of substance use disorders among the transgender 
community (Xavier, 2000). Taken together, this suggests that transgender individuals may have a high need for 
substance abuse treatment, but specific needs or profiles of transgender individuals in treatment are unknown. 
Previous studies examining substance abuse treatment programs were unable to conduct meaningful 
comparisons of transgender and cisgender individuals, as the transgender sample was too small (Cochran and 
Cauce, 2006, Cochran et al., 2008). In sum, we know very little about substance use or substance abuse 
treatment needs among the transgender population, but the limited evidence suggests that transgender 
individuals may be at increased risk for substance use and correspondingly have substance abuse treatment 
needs. 
Meyer's minority stress theory (Meyer, 2003), originally developed to explain increased mental health and 
substance use risk among lesbian, gay, and bisexual individuals, posits that members of minority groups may 
experience additional stress as a result of stigma associated with their minority group membership. This model 
was applied to transgender individuals (Hendricks & Testa, 2012), and suggests that increased experiences of 
prejudice, expectations of experiencing prejudice, concealment of one's minority status, and internalization of 
social stigma are processes that put transgender individuals at risk for poorer health, substance use, and mental 
health outcomes. Research indicates that transgender individuals experience increased prejudice, in the form of 
extremely high rates of physical abuse, sexual assault, employment discrimination (Herbst et al., 2008), and 
harassment (Factor and Rothblum, 2008, Grant et al., 2011). Additionally, research suggests high rates of 
concealment of gender identity among transgender people (Maguen, Shipherd, Harris, & Welch, 2007) in an 
effort to avoid conflict, harassment and intimidation (Beemyn & Rankin, 2011). Taken together, these findings 
suggest that transgender individuals may be subject to minority stress and may therefore experience increased 
severity of substance use and poorer mental health and health outcomes. In line with this theory, meta-analytic 
evidence estimates that transgender individuals, in particular male to female individuals (individuals assigned 
birth sex of male but with an identified gender of female), are at elevated risk for HIV and sexually transmitted 
disease infection (Herbst et al., 2008). Additionally, emerging evidence demonstrates that among transgender 
persons, there are higher rates of non-medical use of prescription drugs among those experiencing 
discrimination based on transgender identity, or mood or anxiety symptoms (Benotsch et al., 2013). 
The present study advances the research by comparing characteristics of transgender and cisgender persons 
entering substance abuse treatment in order to provide a profile of the transgender population on 
characteristics that could influence substance abuse treatment. To our knowledge, this is the first investigation 
to make such comparisons and as such our analyses are exploratory. Using existing theory and research we 
anticipated that after controlling for age, ethnicity, and race, transgender individuals would endorse unique 
psychosocial characteristics related to treatment including less paid work, higher legal system involvement, 
higher likelihood of living with a substance user, fewer children under 17, less involvement in recovery oriented 
activities, and more family conflict. In addition, based on prior research and theory it was expected that 
transgender individuals would evidence increased risk for engagement in health risk behaviors and report 
greater medical and mental health problems and healthcare service utilization. While exploratory in nature due 
to limited available research, we anticipated that there would be differences in primary substance for which 
treatment was being sought and route of administration for transgender individuals. Given that psychosocial 
challenges faced by transgender men and women can differ considerably (Lev, 2004), we considered 
transgender men and women separately. 
2. Methods 
This study used data from the County of San Francisco, and included admission records for all clients entering 
publically funded substance abuse treatment services at one of up to 62 programs in the County of San 
Francisco from July 2007 through December 2009 (N = 14,015). The database was compiled from the mandatory 
entries of substance abuse counselors on the characteristics of their clients, obtained from clients at intake. The 
County of San Francisco released a de-identified version of the database to our research team to facilitate this 
research. This study was exempt from the University of California Committee on Human Research review, as it 
used de-identified data. 
Within the database, clients had unique identifiers to prevent the duplication of client records. For clients who 
sought treatment during the specified time period, data on multiple treatment episodes within the county were 
available. For each individual, the most recent treatment episode was selected for use in these analyses (from 
107,470 total treatment episodes). 
2.1. Measures 
The database included questions from the California Outcomes Measurement System (CALOMS). CALOMS is a 
California statewide data collection system that was designed to meet multiple data recording and reporting 
requirements including: Treatment Episode Data Sets, California Alcohol and Drug Data Set, and National 
Outcome Measures. CALOMS was implemented in 2006 to provide a consistent form of measurement across 
California to evaluate substance abuse treatment programs. CALOMS queries multiple areas including: client 
race, ethnicity, employment and educational status, legal system involvement (e.g., not involved with the legal 
system versus on probation, parole, diversion, or awaiting trial), whether the individual lives with a substance 
user, parental status, whether the individual is involved in activities supportive of recovery (such as 12-step 
meetings), needle use, whether or not the individual has been tested for HIV, self reported Hepatitis C and 
sexually transmitted disease status, hospital and emergency room use, whether or not the individual has a 
mental health diagnosis, medication use for mental health, inpatient and emergency mental health services 
used, primary drug for which the individual is seeking treatment and frequency of use, age that this substance 
was first used, and mode of administration of this substance. CALOMS data are recorded upon client admission 
based on client self-report. For clients who are in the same treatment program for more than one year, an 
annual update may replace initial client admission information (this was done before the data was released to 
the researchers). Many variables are measured over the 30 days prior to admission, treatment update, or 
discharge (for example, for substance use measurement the question is “how many days in the past 30 days has 
the client used the primary drug?” and when measuring mental health emergency room use, the question is 
“how many times in the past 30 days has the client received outpatient emergency services for mental health 
needs?”). CALOMS data has been used in multiple studies reported in peer-reviewed literature (Brecht and 
Urada, 2011, Conner et al., 2011, Evans et al., 2012, Gonzales et al., 2011, Swartz, 2010). It has also undergone a 
complete independent evaluation by Integrated Substance Abuse Programs at the University of California, Los 
Angeles (Rawson, Gonzales, Brecht, Crèvecoeur-MacPhail, & Hemberg, 2008). 
Questions querying gender identity and sexual orientation are not included in CALOMS. The County of San 
Francisco added these questions to the data collection for their county's programs. Thus, gender identity and 
sexual orientation data are not available at the state level, only at the county level. When reporting gender 
identity, participants were offered four options: “male to female,” “female to male,” “not transgender,” and 
“decline to answer.” The term female to male is used to denote an individual with an assigned birth sex of 
female and identified gender of male, while the term male to female indicates an assigned birth sex of male and 
identification with the female gender. For the purpose of this study, individuals who identified as male to female 
were designated transgender women, while individuals who identified as female to male were designated 
transgender men. Individuals who endorsed “decline to answer” when gender identity was queried could 
represent both transgender individuals who do not represent a dichotomous gender identification and 
individuals who do not understand the question. Thus, individuals who declined to answer the question about 
gender identity are not included in this study. Participants had six options when reporting their sexual 
orientation: “heterosexual,” “gay: male/male,” “lesbian: female/female,” “bisexual,” “decline to answer,” and 
“unsure.” 
2.2. Participants 
There were 14,015 individuals with unique identifiers. Participants received services between July 2007 and 
December 2009 at one or more of the substance abuse treatment programs operated or funded by the 
Department of Public Health of San Francisco. Participants were included if they presented for substance abuse 
treatment and have data in the database. 
2.3. Analyses 
All analyses were conducted separately by identified gender. Specifically, individuals who endorsed female sex 
and reported they were “not transgender” (hereafter referred to as cisgender women) were compared to 
individuals who endorsed “Male to female” on transgender status (hereafter referred to as transgender 
women). Similarly, individuals who endorsed male sex and indicated they were “not transgender” (hereafter 
referred to as cisgender men) were compared to individuals who endorsed “Female to male” gender identity 
(hereafter referred to as transgender men). 
Chi-square analyses were used to identify differences in race, ethnicity, and sexual orientation for transgender 
and cisgender men and women; multiple regression analyses were used to identify if transgender status 
predicted current age. Logistic regression analyses were used to identify differences in dichotomous variables 
between cisgender and transgender men and women in substance abuse treatment at admission (full listing of 
variables is in Table 2, Table 3). Multinomial regression analyses were used to predict primary substance of 
abuse (“other substance” was the reference category) and route of administration for the primary substance 
(“inhalation” was the reference category). Linear regression analyses used transgender status to predict 
continuous outcome variables (years of education, age first used primary drug). Days of use of primary drug 
prior to entering treatment was examined in a two part process. First chi-square analyses compared those who 
endorsed no use versus those who endorsed 1–30 days of use. Next, those who endorsed 1 or more days of use 
were retained for linear regression analyses using transgender status to predict days of use. Within all analyses 
(aside from chi-square analyses) age, race, and ethnicity were selected a priori to be entered into the models as 
covariates to control for their effects on the outcome variables of interest. Race and ethnicity were 
dichotomized (non-White and Hispanic were entered into the models as separate covariates) to enhance the 
stability of the models. Due to the large number of analyses, the alpha level was set at p = .01 to minimize type I 
error. In accordance with convention, 95% confidence intervals are reported for all analyses, but only analyses 
that met the more stringent p < .01 criterion were determined to have rejected the null hypothesis. 
3. Results 
3.1. Demographics and referral source 
Complete demographic information and referral source for treatment is reported in Table 1; notable results or 
results not covered in the table are reported here. The "Total" column in Table 1 reports demographic 
information for the entire sample, including individuals who did not answer gender identity questions and thus 
were not retained for subsequent analyses. Transgender men were younger (M = 26.92, SD = 10.79) than 
cisgender men (M = 39.27, SD = 13.20, B = − 12.07, semi-partial R2 = .005, p < .001), while there were no 
detectable differences between transgender and cisgender women (M = 37.78, SD = 11.78 for transgender 
women, M = 35.36, SD = 13.73 for cisgender women; B = 2.49, semi-partial R2 = .001, p = .025). Notably, some 
transgender individuals reported their current sex in a manner that was congruent with their sex assigned at 
birth (n = 81, 40.7%), while others identified their current sex in a manner that was incongruent with their sex 
assigned at birth but consistent with their current gender identity (n = 83, 41.7%). Additionally, 34 (17.1%) of the 
transgender treatment-seekers identified their sex as “other.” Most of the transgender individuals (n = 115, 
57.8%) reported a non-White race, and some reported a Hispanic or Latino ethnicity (n = 48, 24.1%). Among 
men, transgender individuals were more likely to endorse a White race than cisgender men (non-White versus 
White, X2 [1] = 7.04, p = .008) but did not differ from cisgender individuals on ethnicity (Hispanic/Latino versus 
non-Hispanic/Latino, X2 [1] = 2.24, p = .135). Among women, neither race nor ethnicity differed by transgender 
status (non-White versus White, X2 [1] = 2.07, p = .151; non-Hispanic/Latina versus 
Hispanic/Latina, X2 [1] = 1.43, p = .231). Transgender men were far more likely to endorse non-heterosexual 
sexual orientations than cisgender men (61.0% versus 10.9%, X2 [1] = 104.11, p < .001). This effect was also 
observed for women, with 42.9% of transgender women reporting a non-heterosexual orientation, while only 
11.6% of cisgender women reported a non-heterosexual sexual orientation (X2 [1] = 114.54, p < .001) There was 
no difference between transgender and cisgender men (B = .508, semi-partial R2 < .001, p = .127) or women 
(B = − .066, semi-partial R2 < .001, p = .740) in the number of years of education. Of the entire sample, 287 
individuals (2 of which were transgender) had valid dates indicating that an annual update had been performed 
on their treatment record, and some individuals were in treatment longer than one year without an annual 
update. 
Table 1. Demographic and referral source by gender and transgender status.  
Total 
(N = 14,015) 
Cisgender 
women 
(n = 4011) 
Transgender 
women 






(n = 9429) 
Transgender 
men (n = 53) 
Comparisons 
among men 
Age (M, SD) 38.31 (13.54) 35.36 (13.73) 37.78 (11.78) p = .025 39.27 (13.20) 26.92 (10.79) p < .001 
Reported sex (n, %) 
       
 Male 9774 (69.7%) n/a 72 (49.3%) 
 
9429 (100%) 23 (43.4%) 
 
 Female 4193 (29.9%) 4011 (100%) 60 (41.1%) 
 
n/a 9 (17.0%) 
 
 Other 46 (0.3%) n/a 14 (9.6%) 
 
n/a 20 (37.7%) 
 
 Unknown 2 (0.01%) n/a 0 (0.0%) 
 
n/a 1 (1.9%) 
 
Race (n, %) 
   
p = .151a 
  
p = .008a 
 White 5039 (36.0%) 1284 (32.0%) 55 (37.7%) 
 
3494 (37.1%) 29 (54.7%) 
 
 Black 5069 (36.2%) 1558 (38.8%) 39 (26.7%) 
 
3344 (35.5%) 6 (11.3%) 
 
 Native American/Alaska 
native 
186 (1.3%) 74 (1.8%) 4 (2.7%) 
 
104 (1.1%) 0 (0.0%) 
 
 Asian American/Pacific 
Islander 
771 (5.5%) 201 (5.0%) 5 (3.4%) 
 
549 (5.8%) 1 (1.9%) 
 
 Multi racial 722 (5.2%) 282 (7.0%) 14 (9.6%) 
 
411 (4.4%) 8 (15.1%) 
 
 Other race 2227 (15.9%) 612 (15.3%) 29 (19.9%) 
 
1526 (16.2%) 9 (17.0%) 
 
Ethnicity(n, %) 
   
p = .231a 
  
p = .135a 
 Not Hispanic 11,388 (81.3%) 3237 (80.7%) 112 (76.7%) 
 
7692 (81.6%) 39 (73.6%) 
 
 Mexican/Mexican American 1134 (8.1%) 336 (8.4%) 12 (8.2%) 
 
749 (7.9%) 5 (9.4%) 
 
 Cuban 68 (0.5%) 9 (0.2%) 4 (2.7%) 
 
52 (0.6%) 1 (1.9%) 
 
 Puerto Rican 197 (1.4%) 73 (1.8%) 5 (3.4%) 
 
117 (1.2%) 0 (0.0%) 
 
 Other Hispanic/Latino 1228 (8.8%) 356 (8.9%) 13 (8.9%) 
 
819 (8.7%) 8 (15.1%) 
 
Sexual orientation(n, %) 
   
p < .001a 
  
p < .001a 
 Heterosexual 11,984 (85.5%) 3452 (86.1%) 76 (52.1%) 
 
8318 (88.2%) 16 (30.2%) 
 
 Gay male/male 868 (6.2%) 22 (0.5%) 31 (21.2%) 
 
797 (8.5%) 12 (22.6%) 
 
 Lesbian female/female 173 (1.2%) 156 (3.9%) 8 (5.5%) 
 
1 (< 0.1%) 4 (7.5%) 
 
 Bisexual 523 (3.7%) 273 (6.8%) 18 (12.3%) 
 
215 (2.3%) 9 (17.0%) 
 
 Decline to answer 238 (1.7%) 72 (1.8%) 4 (2.7%) 
 
62 (0.7%) 9 (17.0%) 
 
 Unsure 95 (0.7%) 36 (0.9%) 9 (6.2%) 
 
36 (0.4%) 3 (5.7%) 
 
Mean years of education (M, 
SD) 
11.92 (2.54) 11.69 (2.54) 11.77 (2.63) p = .740 12.02 (2.52) 12.19 (3.14) p = .127 
Referral source(n, %) 
       
 Self 3239 (26.6%) 1185 (33.2%) 46 (35.9%) 
 
1835 (22.8%) 19 (36.5%) 
 
 Family or friend 501 (4.1%) 222 (6.2%) 7 (5.5%) 
 
262 (3.2%) 4 (7.7%) 
 
 Other substance abuse 
treatment 
3599 (29.6%) 707 (19.8%) 20 (15.6%) 
 
2782 (34.5%) 2 (3.8%) 
 
 Court or criminal justice 1535 (12.6%) 330 (9.2%) 8 (6.3%) 
 
1169 (14.5%) 3 (5.8%) 
 
 Health, social, community 
service 
2413 (19.8%) 759 (21.2%) 40 (31.3%) 
 
1536 (19.0%) 18 (34.6%) 
 
 Employer or school 544 (4.5%) 235 (6.6%) 3 (2.3%) 
 
294 (3.6%) 3 (5.8%) 
 
 Other 330 (2.7%) 134 (3.8%) 4 (3.1%) 
 
186 (2.3%) 3 (5.8%) 
 
aComparisons of race, ethnicity, and sexual orientation were dichotomized (i.e., White vs. non-White, Hispanic/Latino vs. non-Hispanic/Latino, and 
heterosexual vs. non-heterosexual). 
3.2. Psychosocial factors related to treatment 
Complete results of logistic and multinomial regression analyses are documented in Table 2, Table 3. 
Transgender men differed from cisgender men on many psychosocial factors; they were more likely to have 
been paid for work in the previous 30 days, less likely to have been involved with the legal system (e.g., less 
likely to be on parole, probation, awaiting trial, or on diversion), more likely to be living with a substance user in 
the previous 30 days, and more likely to have experienced family conflict in the 30 days prior to treatment. 
Among women, transgender individuals were less likely to have children under the age of 17, but there were no 
differences on any of the other psychosocial variables. 
Table 2. Logistic regression comparing cisgender (reference group) and transgender women entering substance 
abuse treatment: adjusted for age, race, and ethnicity.  
Cisgender n (%) Transgender 
n (%) 
Adj. OR 95% CI 
Psychosocial factors 
    
 Paid work in past 30 days 444 (11.5%) 10 (6.9%) 0.56 0.29, 1.07 
 Involved with legal system 1184 (29%) 51 (34.9%) 1.35 0.95, 1.92 
 Living with substance user in past 30 days 462 (12.0%) 24 (16.6%) 1.42 0.90, 2.23 
 Children under 17 1351 (33.7%) 9 (6.2%) 0.13⁎⁎ 0.07, 0.25 
 Involved in recovery oriented activities in past 
30 days 
808 (20.8%) 40 (27.6%) 1.36 0.94, 1.99 
 Family conflict in past 30 days 526 (13.8%) 18 (12.4%) 0.93 0.56, 1.56 
Health risk behaviors 
    
 Used needles in past year 1106 (30.8%) 60 (43.8%) 1.70⁎ 1.18, 2.43 
 Diagnosed with Hepatitis C 378 (9.7%) 13 (9.0%) 0.80 0.44, 1.45 
 Diagnosed with any sexually transmitted disease 86 (2.2%) 6 (4.1%) 1.79 0.77, 4.18 
 Tested for HIV 2671 (71.4%) 127 (88.2%) 2.83⁎⁎ 1.67, 4.81 
Medical and mental health service utilization 
    
 ER visit in last 30 days 415 (10.7%) 24 (16.6%) 1.52 0.96, 2.39 
 Hospital overnight for medical in past 30 days 203 (5.2%) 11 (7.6%) 1.36 0.72, 2.58 
 Physical health problems past 30 days 933 (24.1%) 52 (35.9%) 1.64⁎ 1.14, 2.34 
 Outpatient emergency mental health care past 
30 days 
121 (3.1%) 6 (4.1%) 1.24 0.53, 2.87 
 Hospital or psychiatric facility for mental health 
in past 30 days 
145 (3.7%) 8 (5.5%) 1.42 0.68, 2.95 
 Prescribed medication for mental health in past 
30 daysa 
897 (23.1%) 59 (40.7%) 2.13⁎⁎ 1.50, 3.03 
 Ever diagnosed with mental illnessa 1489 (40.0%) 88 (61.1%) 2.28⁎⁎ 1.60, 3.24 
Substance use: Primary problem 
    
 Alcohol 790 (19.7%) 29 (19.9%) 2.12 0.64, 7.03 
 Cocaine 817 (20.4%) 29 (19.9%) 2.21 0.66, 7.38 
 Heroin 1075 (26.8%) 32 (21.9%) 1.69 0.51, 5.59 
 Methamphetamine 395 (9.8%) 38 (26.0%) 6.04⁎ 1.84, 19.90 
 Marijuana 369 (9.2%) 7 (4.8%) 1.85 0.46, 7.42 
 Other drug 182 (4.5%) 3 (2.1%) ref ref 
Primary substance: Route of administration 
    
 Inhaled 198 (5.5%) 7 (5.1%) ref ref 
 Injection 1061 (29.7%) 46 (33.6%) 1.16 0.51, 2.62 
 Oral 952 (26.6%) 32 (23.4%) 0.91 0.40, 2.10 
 Smoking 1363 (38.1%) 52 (38.0%) 1.18 0.53, 2.64 
aAnalyses involving mental health diagnoses and medications for mental health conditions should be interpreted 
with caution, as many transgender individuals may have diagnoses of or medications for Gender Identity 
Disorder per DSM-IV-TR (American Psychiatric Association, 2000). 
⁎p < .01. 
⁎⁎p < .001. 
 
Table 3. Logistic regression comparing cisgender (reference group) and transgender men entering substance 
abuse treatment: adjusted for age, race, and ethnicity. 
 




    
 Paid work in past 30 days 1375 (15.0%) 18 (34.6%) 2.30⁎ 1.29, 4.12 
 Involved with legal system 3775 (40.2%) 6 (11.3%) 0.14⁎⁎ 0.06, 0.33 
 Living with substance user in past 30 days 886 (9.7%) 21 (40.4%) 5.26⁎⁎ 2.99, 9.25 
 Have children under 17 2024 (21.5%) 4 (7.5%) 0.31 0.11, 0.86 
 Involved in recovery oriented activities in 
past 30 days 
1982 (21.6%) 16 (30.8%) 1.84 1.01, 3.34 
 Family conflict in past 30 days 693 (7.6%) 17 (32.7%) 4.29⁎⁎ 2.36, 7.81 
Health risk behaviors 
    
 Used needles in past year 2573 (28.5%) 8 (19.5%) 0.68 0.30, 1.50 
 Diagnosed with Hepatitis C 688 (7.5%) 2 (3.9%) 1.01 0.24, 4.26 
 Diagnosed with any sexually transmitted 
disease 
180 (2.0%) 2 (3.9%) 2.24 0.53, 9.42 
 Tested for HIV 6411 (70.6%) 40 (78.4%) 2.28 1.15, 4.51 
Medical and mental health service 
utilization 
    
 ER visit in last 30 days 989 (10.8%) 6 (11.5%) 1.42 0.60, 3.36 
 Hospital overnight for medical in past 
30 days 
500 (5.4%) 3 (5.8%) 1.52 0.47, 4.96 
 Physical health problems past 30 days 2099 (22.8%) 17 (32.7%) 2.38⁎ 1.30, 4.33 
 Outpatient emergency mental health care 
past 30 days 
219 (2.4%) 1 (1.9%) 0.87 0.12, 6.35 
 Hospital or psychiatric facility for mental 
health in past 30 days 
305 (3.3%) 4 (7.7%) 2.69 0.95, 7.59 
 Prescribed medication for mental health in 
past 30 daysa 
1583 (17.2%) 19 (36.5%) 3.30⁎⁎ 1.84, 5.94 
 Ever diagnosed with mental illnessa 2813 (31.1%) 28 (53.8%) 2.88⁎⁎ 1.63, 5.08 
Substance use: Primary problem 
    
 Alcohol 2423 (25.7%) 15 (28.3%) 0.87 0.25, 3.07 
 Cocaine 2163 (22.9%) 8 (15.1%) 0.75 0.19, 2.95 
 Heroin 2220 (23.5%) 8 (15.1%) 0.70 0.18, 2.70 
 Methamphetamine 1025 (10.9%) 3 (5.7%) 0.29 0.06, 1.45 
 Marijuana 916 (9.7%) 5 (9.4%) 0.34 0.08, 1.52 
 Other drug 339 (3.6%) 3 (5.7%) ref ref 
Primary substance: Route of administration 
    
 Inhaled 594 (6.6%) 2 (4.9%) ref ref 
 Injection 2315 (25.7%) 8 (19.5%) 1.28 0.27, 6.17 
 Oral 2750 (30.5%) 16 (39.0%) 1.73 0.40, 7.61 
 Smoking 3345 (37.2%) 15 (36.6%) 1.31 0.30, 5.79 
aAnalyses involving mental health diagnoses and medications for mental health conditions should be interpreted 
with caution, as many transgender individuals may have diagnoses of or medications for Gender Identity 
Disorder per DSM-IV-TR (American Psychiatric Association, 2000). 
⁎p < .01. 
⁎⁎p < .001. 
 
3.3. Health risk behaviors 
Transgender women were more likely than cisgender women to have used needles in the previous year and 
were more likely to have been tested for HIV. Transgender men had higher odds of being tested for HIV than 
cisgender men, but not at a level that met the criterion p < .01 (AdjOR = 2.28; 95% CI = 1.15, 4.51, p = .018). There 
were no detectable differences in rates of reported Hepatitis C diagnoses or sexually transmitted disease 
diagnoses. 
3.4. Medical and mental health status and service utilization 
Both transgender men and women were more likely than cisgender men and women to report experiencing 
physical health problems in the 30 days prior to treatment. Individuals who identified as transgender had no 
detectable differences in emergency room (ER) visits, overnight stays for medical conditions, outpatient 
emergency mental health care, or psychiatric hospitalizations in the 30 days prior to treatment. Transgender 
men and women were more likely to report having been prescribed medication for mental health in the 
previous 30 days and having been diagnosed with a mental illness. 
3.5. Substance use behaviors 
Transgender status was not predictive of the age the individual first used the primary drug they were seeking 
treatment for in men (transgender M = 15.68, SD = 11.67 versus cisgender M = 18.96, SD = 9.24; B = − .283, 
semi-partial R2 < .001, p = .812) nor in women (transgender M = 19.47, SD = 9.93 versus 
cisgender M = 17.84, SD = 9.84; B = .795, semi-partial R2 < .001, p = .261). When considering primary substance 
of abuse, transgender status did not predict higher odds of a specific primary substance of abuse for men, but 
among women, transgender status predicted primary methamphetamine use. Neither transgender men(X2 [1] = 
0.28, p = .598) nor transgender women (X2 [1] = 0.00, p = .984) were more or less likely than their cisgender 
counterparts to report having used their primary substance in the 30 days prior to treatment. Among individuals 
who had used their primary substance in the month prior to treatment, transgender status did not predict the 
number of days of use among men (M = 13.03, SD = 11.52 for transgender men, M = 16.09, SD = 11.50 for 
cisgender men, B = − 2.957, semi-partial R2 < .001, p = .129), nor among women (M = 13.94, SD = 11.71 for 
transgender women, M = 16.95, SD = 11.69 for cisgender women, B = − 2.747, semi-partial R2 = .002, p = .038). 
4. Discussion 
This study identified several unique characteristics of transgender individuals entering substance abuse 
treatment. To our knowledge, this is the first large-scale study to examine differences between transgender and 
cisgender individuals who are entering substance abuse treatment. Previous studies of individuals entering 
substance abuse treatment that have included transgender persons had too small of a transgender sample to 
detect differences based on transgender status (as in Cochran & Cauce, 2006) or had to drop transgender 
individuals from analyses (as in Cochran et al., 2008), and the epidemiological research has not historically 
documented gender identity. 
4.1. Demographics 
Consistent with previous research (i.e., Clements-Nolle, Marx, Guzman, & Katz, 2001), individuals who identified 
as transgender had variable responses to reported sex and to sexual orientation. First, within the transgender 
groups, more individuals identified their sex as “other.” It is important for substance abuse treatment providers 
and researchers to be careful not to provide labels for individuals wherein none fit. For example, these 
participants were asked to endorse either a male to female or female to male category. It is possible that these 
two categories do not align with the preferred gender identities of these individuals. Some individuals who do 
not identify with their sex assigned at birth may have “declined to answer” the question about gender identity 
due to the limited options available. Allowing for a non-binary response option for gender identity can result in a 
wealth of responses (see Harrison, Grant, Herman, Dodge, & Imse, 2011 for a discussion), which may be more 
accurate to the individual. 
Transgender men presenting for substance abuse treatment were considerably younger to a degree that is likely 
to be of clinical significance (mid-20s for transgender men versus mid 30s for transgender women and cisgender 
individuals). It is possible that this was a cohort trend within the San Francisco area, meaning that there were 
more young transgender men in this geographical area at this time, that transgender men were experiencing an 
earlier onset of substance abuse problems, or that this particular cohort was willing to identify as transgender at 
a younger age. Alternatively, this finding may suggest a willingness to seek treatment earlier. Previous research 
has noted a relationship between age seeking treatment and number of previous treatment episodes, with 
fewer episodes being associated with a younger age (Cacciola, Dugosh, & Camilleri, 2009), thus this could 
represent a treatment group that is more successful in an earlier episode and thus does not return to treatment 
for additional episodes. 
4.2. Psychosocial considerations related to treatment 
Transgender men evidenced strengths that may impact treatment: they were more likely to have recent paid 
employment and less likely to have ongoing legal issues. When considered with the younger treatment seeking 
age, it is possible that transgender men are entering treatment with more resources likely to support successful 
treatment. The finding that transgender men were less likely to have ongoing legal issues may have important 
implications for treatment. This suggests that transgender men may be more likely to enter treatment with a 
“clean slate” and less likely to have to deal with the repercussions of drug related charges during and after 
treatment, or of the ongoing stress associated with being on parole or probation. 
Transgender men were, however, more than 5 times as likely as cisgender men to have been living with a 
substance abuser. This implyies that transgender men may require additional support while in outpatient 
treatment, or when leaving residential treatment, as previous research has suggested poorer treatment 
outcomes for individuals in a cohabitating relationship with a substance abuser (Fals-Stewart, Birchler, & 
O'Farrell, 1999). Transgender individuals may also be more reliant than cisgender individuals on communities 
that are non-family, as they have been shown to experience their families of origin as less supportive (Factor & 
Rothblum, 2008) and experience high rates of rejection from families (Grant et al., 2011), thus the power of non-
birth family relationships should be considered in treatment settings. Consistent with this finding, transgender 
men reported higher levels of family conflict than did cisgender individuals, however this effect was not 
observed in transgender women. Some of this effect could be related to the higher incidence of living with a 
substance user, as the term “family” within this question was not defined. Notably, despite previous research 
citing higher levels of employment related discrimination for transgender individuals (Herbst et al., 2008), within 
a substance abuse treatment setting, transgender women living in San Francisco did not appear to differ from 
cisgender women on paid days of work just prior to entering treatment, and transgender men fared better than 
cisgender men. 
4.3. Health risk behaviors 
Consistent with previous research (Edwards, Fisher, & Reynolds, 2007), transgender women reported higher 
rates of needle use in the past year. Despite higher levels of needle use within the last year, transgender women 
were not more likely to report injection use of the primary substance for which they were seeking treatment. 
This points to the possibility that needle use may be involved in administration of medications, such as 
hormones, which is consistent with previous research reporting higher rates of injection of hormones than 
street drugs (Herbst et al., 2008). Future research is needed to elucidate the needle use practices of transgender 
women and identify the specific substances for which needles are used and/or shared. Transgender women 
were also more likely to have been tested for HIV. Collectively, these findings suggest that while transgender 
women are engaging in higher rates of needle use, they may be more likely to engage in proactive health 
behaviors (e.g., HIV testing). Future targeted research is necessary to clarify this relationship. 
4.4. Medical and mental health status and service utilization 
Greater reports of physical health problems among both transgender women and men indicate that transgender 
individuals entering substance abuse treatment may have unique healthcare needs that need to be addressed. 
One potential pathway to increased health problems among this community could be the experience of minority 
stress. Additional research to elucidate the role of minority stress in health outcomes for transgender individuals 
is warranted. 
It is difficult to interpret the finding that transgender men and women have higher rates of mental health 
diagnoses and use of psychiatric medications, as it is not possible (within this dataset) to identify whether these 
diagnoses are for Gender Identity Disorder (as defined by the Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV-TR, American Psychiatric Association, 2000) or a different mental health disorder. Such 
findings may be directly related to transgender status, and not other psychiatric conditions. As such, these 
results should be interpreted with caution. That being said, existing research with transgender individuals does 
suggest that psychological distress is predictive of nonmedical use of prescription medication, which is in turn 
associated with illicit drug use (Benotsch et al., 2013). Overall, the findings of increased physical health 
problems, mental health diagnoses, and mental health medications indicate that substance abuse programs 
need to be prepared to link transgender clients to care for both physical and mental health. 
4.5. Substance use behaviors 
Transgender women were more than 6 times as likely to be seeking treatment for methamphetamine use, but 
aside from that there were no differences in the primary substance for which transgender and cisgender men 
and women were seeking treatment. Increased treatment seeking for methamphetamine use may indicate a 
greater need for methamphetamine prevention among transgender women. Previous research has found an 
association between stimulant use and substance use in the context of sexual activity among transgender 
women (Sevelius, Reznick, Hart, & Schwarcz, 2009). Treatment providers for transgender women should assess 
for and potentially address the relationship between sexual activity and methamphetamine use among this 
population. 
4.6. Limitations 
This study took place in the urban area of San Francisco, and thus the results reported here are not necessarily 
generalizable to other areas of the country. San Francisco is known to be more embracing of diverse gender 
identities than many areas of the country (evidenced by structural components such as several transgender 
specific health clinics and organizations) and thus represents an atypical environment for transgender 
individuals. It is possible that effects due to minority stress would likely be lessened in this geographic area, but 
this hypothesis would require additional confirmatory research. This study is also limited by self-report 
measures and by utilizing records obtained in a large county health data management system. As such, the data 
collection process was at times inconsistent (e.g., annual updates of admissions data were not performed 
consistently). Despite these limitations, there is no expectation that self-report or data errors would vary by 
gender identity, thus any effects (over-reporting or under-reporting) are likely to be equally distributed within 
the sample and not to differ systematically by gender identity. It is also important to note that this is a 
treatment-seeking sample, which is not generalizable to all individuals with substance abuse problems. Finally, 
the measure of gender identity only allowed two response options for transgender individuals: FTM and MTF. 
Additional response options likely would have yielded more individuals who may have identified as transgender. 
The reporting of gender identity may be impacted by the modality in which it is collected (e.g., self-report versus 
computer assisted interview). While researchers have began to discuss ways to measure gender identity in 
health settings (Cahill & Makadon, 2014), more research is needed on the measurement of gender identity. 
4.7. Future directions 
This study identified multiple differences between transgender and cisgender persons in basic demographics, 
psychosocial characteristics, health risk behaviors, health and mental healthcare utilization, and substance use 
behaviors. Despite the evidence that points to minority stress processes among the transgender community, 
there may also be sources of resilience among transgender people and minority communities, such as 
“community cohesiveness” (Meyer, 2003, p. 677), which may reduce minority stressors. This suggests that while 
transgender individuals may experience increased stress, they may also have unique sources of strength and 
resilience. This study provided an initial foundation to elucidate potential strengths within this community, while 
identifying important avenues for future research. 
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1The term “transgender” can have multiple meanings; it is commonly used to describe people who express their 
gender in ways that are incongruent with their biological sex and/or society's dichotomous, male-or-
female conceptualization of gender. 
 
